Cargando…

Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab

A patient with COVID-19-related severe respiratory failure, with insufficient response to an antiretroviral therapy, hydroxychloroquine and Interleukin-6 (IL-6) antagonist therapy, presented a prompt resolution of the respiratory function and improvement in the radiological picture after baricitinib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cingolani, A., Tummolo, A. M., Montemurro, G., Gremese, E., Larosa, L., Cipriani, M. C., Pasciuto, G., Liperoti, R., Murri, R., Pirronti, T., Cauda, R., Fantoni, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2020
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7340855/ https://www.ncbi.nlm.nih.gov/pubmed/32642806 http://dx.doi.org/10.1007/s15010-020-01476-7

Ejemplares similares

Sarilumab use in severe SARS-CoV-2 pneumonia
por: Gremese, Elisa, et al.
Publicado: (2020)

Safety and Outcomes With Combination Therapy With Sarilumab and Baricitinib for Severe COVID-19 Respiratory Infection in Cancer Patients
por: Velez, Ana Paula, et al.
Publicado: (2023)

Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis
por: Albuquerque, Arthur M., et al.
Publicado: (2023)

Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial
por: Emery, Paul, et al.
Publicado: (2020)

Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2021)

Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections
por: Sweeney, Daniel A, et al.
Publicado: (2023)

Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019
por: Titanji, Boghuma K, et al.
Publicado: (2020)

Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study)
por: Mastrorosa, Ilaria, et al.
Publicado: (2023)

Sarilumab: Cytomegalovirus colitis: case report
Publicado: (2020)

Sarilumab: patient-reported outcomes in rheumatoid arthritis
por: Crotti, Chiara, et al.
Publicado: (2018)

Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis
por: Xu, Christine, et al.
Publicado: (2019)

Sarilumab: Perforated duodenal ulcer: case report
Publicado: (2021)

Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment
por: Genovese, Mark C, et al.
Publicado: (2019)

Baricitinib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Janus Kinases
por: Mayence, Annie, et al.
Publicado: (2019)

Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis
por: de Bruin-Weller, Marjolein S., et al.
Publicado: (2022)

Dexamethasone to the rescue
por: Moon, Chang
Publicado: (2020)

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
por: Raimondo, Maria Gabriella, et al.
Publicado: (2017)

Pain Reduction in Rheumatoid Arthritis Patients Who Use Opioids: A Post Hoc Analysis of Phase 3 Trials of Baricitinib
por: Pope, Janet E., et al.
Publicado: (2021)

Real-World Analysis of Therapeutic Patterns in Patients Affected by Rheumatoid Arthritis in Italy: A Focus on Baricitinib
por: Perrone, Valentina, et al.
Publicado: (2020)

Association between Older Age and Psychiatric Symptoms in a Population of Hospitalized Patients with COVID-19
por: Cipriani, Maria Camilla, et al.
Publicado: (2023)

Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis
por: Emery, Paul, et al.
Publicado: (2019)

Disease–Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis
por: Lee, Eun Bong, et al.
Publicado: (2016)

Sarilumab: Thrombocytopenia during an off-label use: case report
Publicado: (2020)

Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review
por: Chamlagain, Rajan, et al.
Publicado: (2021)

Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations
por: Marino, Andrea, et al.
Publicado: (2022)

Baricitinib and the Risk of Incident Interstitial Lung Disease: A Descriptive Clinical Case Report from Clinical Trials
por: Salvarani, Carlo, et al.
Publicado: (2021)

Real-Life Effectiveness and Tolerance of Baricitinib for the Treatment of Severe Alopecia Areata with 1-Year Follow-Up Data
por: De Greef, Axel, et al.
Publicado: (2023)

Clinical Efficacy of Sarilumab Versus Upadacitinib Over 12 weeks: An Indirect Treatment Comparison
por: Huizinga, Thomas, et al.
Publicado: (2023)

Baricitinib and primary biliary cholangitis
por: Gordon, Stuart C., et al.
Publicado: (2021)

Application of Baricitinib in Dermatology
por: Zhang, Jingya, et al.
Publicado: (2022)

Association and pharmacological synergism of the triple drug therapy baricitinib/remdesivir/rhACE2 for the management of COVID-19 infection
por: Vitiello, Antonio, et al.
Publicado: (2021)

Cefiderocol for Severe Carbapenem-Resistant A. baumannii Pneumonia: Towards the Comprehension of Its Place in Therapy
por: Rando, Emanuele, et al.
Publicado: (2021)

Combined administration of inhaled DNase, baricitinib and tocilizumab as rescue treatment in COVID-19 patients with severe respiratory failure
por: Gavriilidis, Efstratios, et al.
Publicado: (2022)

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes
por: Gabay, Cem, et al.
Publicado: (2020)

Baricitinib for the treatment of rheumatoid arthritis
por: Urits, Ivan, et al.
Publicado: (2020)

Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2023)

Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
por: Taylor, Peter C., et al.
Publicado: (2023)

Rescue technique for complete removal of an accidentally ruptured orbital dumbbell deep dermoid cyst: A case report
por: Lin, Pei-Hsuan, et al.
Publicado: (2018)

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
por: Kalil, Andre C., et al.
Publicado: (2020)

Clinical evaluation of the safety, efficacy and tolerability of sarilumab in the treatment of moderate to severe rheumatoid arthritis
por: Pelechas, Eleftherios, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vmahv8udfmfrmnnigaj6ca224j